Rafferty Asset Management
PRLD icon

Rafferty Asset Management’s Prelude Therapeutics PRLD Stock Holding History

Rafferty Asset Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-36,936
Closed -$1.15M – 1325
2021
Q3 		$1.15M Sell
36,936
-12,844
-26% -$416K 0.01% 777
2021
Q2 		$1.43M Buy
49,780
+1,330
+3% +$47.4K 0.01% 779
2021
Q1 		$2.1M Buy
+48,450
New +$3.21M 0.01% 609

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rafferty Asset Management's PRLD Position: Q4 2021 in Review

Rafferty Asset Management sold out of Prelude Therapeutics (PRLD) in Q4 2021, closing a stake of 36,936 shares — an estimated $1.15M sold.

Rafferty Asset Management first reported a position in PRLD in Q1 2021 and held it in 3 quarters. The position peaked at $2.1M in Q1 2021. 75 funds tracked by Wall St. Rank hold PRLD as of Q4 2021.

  • Rafferty Asset Management reported no remaining Prelude Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Rafferty Asset Management sold 36,936 Prelude Therapeutics shares in Q4 2021, an estimated $1.15M.
  • Rafferty Asset Management first reported a position in Prelude Therapeutics in Q1 2021 and held it in 3 quarters.
  • Rafferty Asset Management's Prelude Therapeutics position peaked at $2.1M in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2021.

Based on Rafferty Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.